ArticleGlia2026
Astrocytic Igfbp2 Promotes Spontaneous Seizures in a Mouse Model of Mesial Temporal Lobe Epilepsy.
Article in Glia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mesial temporal lobe epilepsy (MTLE) is a common, frequently drug-resistant epilepsy characterized by seizures arising from the hippocampus. Its hallmark pathology is hippocampal sclerosis with neuronal loss and reactive astrogliosis. Although astrocytes have emerged as potential targets for antiepileptic therapies, their role in epilepsy development remains poorly defined. Here, we combined adeno-associated virus (AAV)-mediated labeling with translating ribosomal affinity purification (TRAP) to generate astrocyte-enriched transcriptome profiles from sclerotic hippocampal regions in a mouse model of MTLE. This analysis identified a marked upregulation of insulin-like growth factor-binding protein 2 (Igfbp2) in reactive astrocytes. Functional studies revealed that astrocytic Igfbp2 increases the excitability of dentate granule cells and promotes spontaneous recurrent seizures. These findings reveal Igfbp2 as a key astrocytic modulator of hippocampal excitability and identify it as a potential therapeutic target for epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.